M.J. van den Bent

Discipline

Psychologie (5) Economies et finances (1)

Type de document

Articles (17) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Treatment (13) Patients (12) Patients (12) Brain (11) cerveau (11) survie (10) Survival (10) analyse (9) Analysis (9) procès (8) cancer (8) Cancer (8) Methylation (8) Human beings (8) Cancer (8) Methylation (8) Months (7) âge (6) adulte (6) Chemotherapy (6) Radiotherapy (6) Chemotherapy (6) Older people (6) Age (6) Use (6) Age (6) Radiotherapy (6) adulte (6) recherche (5) modèle (5)

Documents écrit par M.J. van den Bent (17) | parle de M.J. van den Bent (0)

DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
P. Bady et al. (24 mars 2022)
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
M. Klein et al. (5 mai 2021)
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.
M.M. Mrugala et al. (2021)
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
N.A. Mohile et al. (22 juil. 2020)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
P. Bady et al.
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
W. Wick et al. (1 oct. 2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
B.G. Baumert et al. (2016)
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.
S. Kurscheid et al. (2015)
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2013)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
M.E. Hegi et al. (2012)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2012)
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
R. Stupp et al. (2011)
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
J. Maringwa et al. (2011)
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
R. Stupp et al. (2008)
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study.
M. Mauer et al. (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R. Stupp et al.
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M. J. van den Bent et al.